Tag: lymph node
SIGN UP FOR OUR NEWS LETTER


Quick Search

Reset

Glen Tisman, MD: Nomograms – Prediction of Lymph Node Involvement with Tumor

Tue 31 Aug 2010

Nomogram 3 Prediction of Lymph Node Involvement with Tumor Caggianos et al3 developed nomograms for the preoperative prediction of lymph node metastases in patients with clinically localized prostate cancer. Their study was a retrospective, nonrandomized analysis of 7,014 patients treated with radical prostatectomy at six institutions between 1985 and 2000. Excluded were patients who hadRead More ›

MRI In Prostate Cancer

Sun 30 Nov 2008

Jelle Barentsz, M.D., Ph.D Professor of Radiology – Chairman for Research Department of Radiology University Medical Center – St. Radboud Nijmegen Nijmegen, The Netherlands Edited from PCRI Insights November, 2008 v 11.4 Editor’s Note: This paper discusses ferumoxtran-10 (Combidex). AMAG Pharmaceuticals has discontinued the manufacture of Ferumoxtran-10 in 2010 making Combidex no longer available. TheyRead More ›

Magnetic Resonance Anatomic and Spectroscopic Imaging of Prostate Cancer – Current Status

Wed 1 Nov 2006

John Kurhanewicz, Christopher K. Sotto and Fergus Coakley Department of Radiology, University of California San Francisco Edited from PCRI Insights November, 2006 vol. 9 no. 4   Magnetic Resonance Imaging (MRI) Development of Magnetic Resonance Imaging (MRI) as a clinically useful technique for the assessment of prostate cancer has been a major focus at theRead More ›

Ferumoxtran-10: An Important New Prostate Cancer Staging Tool

Mon 1 Nov 2004

PCRI Insights November 2004 vol. 7, no. 4 By Maha Torabi, MD and Mukesh G. Harisinghani, MD, Department of Radiology, Massachusetts General Hospital, Boston, MA Editor’s Note: This paper discusses ferumoxtran-10 (Combidex). AMAG Pharmaceuticals has discontinued the manufacture of Ferumoxtran-10 in 2010 making Combidex no longer available. They are currently pursuing approval of ferumoxytol asRead More ›

Update on ProstaScint®: CT and MRI Fusion as Diagnostic Tools

Fri 1 Aug 2003

By Samuel Kipper, M.D., Pacific Coast Imaging, Irvine, CA Reprinted from PCRI Insights August 2003 vol. 6, no. 3 Prostate cancer management has advanced significantly over the last decade, most notably with improved methods of risk stratification, which allow for more appropriate treatment selection for individual patients based on their individual prognostic factors. Some ofRead More ›

The Role of Combined MRI & MRSI in Treating Prostate Cancer

Tue 1 Aug 2000